This report from Life Science Intelligence provides the latest market data for the Global External Pain Pumps Market. Information covered by this report includes:
The global market for external pain pumps was valued at an estimated $290.6 million in 2020 and is projected to increase at a CAGR (2020-2024) of 11.4%. Product segments covered by this report include external infusion pumps and related consumables for pain management.
This report covers the impact of COVID-19 on the external pain pumps market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as B. Braun, Smiths Medical, Avanos, Hospira, and others. The report provides insights into trends, drivers, and limiters of the external pain pumps market, as well as highlights potential opportunities.
The external pain pumps market was negatively impacted by the COVID-19 pandemic. The pandemic has affected elective surgical procedures markedly, as many non-critical procedures have been cancelled or postponed so that healthcare resources have been conserved for the treatment of COVID-19 and other critically ill patients. The market is projected to recover to pre-COVID-19 levels in 2021.
Avanos, Smiths Medical, and B Braun together account for approximately 90% of the global external pain pumps market share in the external pain pumps market. Avanos is the market leader in external pain pumps and has further consolidated its non-opioid pain management portfolio with the acquisition of Game Ready & Summit Medical.
Approximately 400 million surgical procedures are performed across major surgical specialties worldwide. Post-operative pain management is achieved by delivering medication subcutaneously, intravenously, or epidurally through external pain pumps. These devices are considered more effective than oral medication as the medications are delivered directly to the cerebrospinal fluid (CSF).